Abbott's FreeStyle Libre 3 Plus Now Covered Across Canada

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
TMCnet

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.

Should Abbott’s AI-Powered Libre Assist Shift Its Diabetes Platform Strategy Narrative for ABT Investors?

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.

Abbott Fixes Faulty Glucose Monitors

Medical device maker Abbott recalled two glucose monitors that were giving users an incorrect low glucose reading. Over an ...
MobiHealthNews

Abbott's Freestyle Libre system becomes first CGM to be FDA cleared for use without fingersticks

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

Health Canada approves expanded compatibility for mylife Loop with iOS and Abbott's FreeStyle Libre 3 Plus Sensor

Diabetes Care and CamDiab are pleased to announce that Health Canada has approved the use of mylife Loop powered by mylife ...

Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering

Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that ...

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.